+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents), by Test Location, by Technology (PCR, Sequencing, INAAT, TMA), by Application, by Region, and Segment Forecasts, 2022-2030

  • ID: 4764587
  • Report
  • April 2022
  • Region: Global
  • 270 Pages
  • Grand View Research

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GRIFOLs S.A.
  • Hologic, Inc. (Gen Probe)
The global molecular diagnostics market size is expected to reach USD 31.9 billion by 2030, and is expected to decline at a CAGR of -1.6% from 2022 to 2030. The contraction in the market will be due to the decline in demand for molecular testing for COVID-19. However, factors such as the rising geriatric population and increasing demand for technologies such as NGS is expected to drive market growth.



Molecular diagnostics plays an important role in infectious disease testing as they can yield effective and fast results. Hence, the increasing prevalence of hospital-acquired infections & infectious diseases is projected to drive the market over the forecast period. Increasing incidence and awareness regarding genetic disorders is further anticipated to accelerate market growth. The miniaturization of three basic molecular assays-nanobiotechnology, biochips, and microfluidics are expected to increase the accuracy and specificity of diagnostic outcomes, and hence, increase the demand for molecular diagnostic products. These improvements are expected to enhance the availability of PoC molecular diagnostic tests to yield quick and effective test results.

Companies are expanding their product portfolios with the acquisition of smaller companies. For instance, in March 2021, Hologic announced the acquisition of Diagenode-a molecular diagnostic company with a wide range of PCR instruments, facilitating the detection of over 30 bacteria-for USD 159 million. Similarly, in April 2021, F. Hoffmann-La Roche Ltd. acquired GenMark Diagnostics, Inc. at a price of USD 24.05 per share in cash, and it holds around 82.89% of total shares of GenMark Diagnostics. GenMark Diagnostics, Inc. has proprietary technologies, such as eSensor XT-8 and ePlex, which can be utilized in developing tests for infectious diseases, including bloodstream infections.

Key players are enhancing their range of testing options for real-time PCR instruments by increasing R&D activities for the development of kits that target emerging diseases or by entering into agreements with other kit manufacturing companies. These include the introduction of Cobas HPV test assay in Cobas 4800 by Roche Diagnostics. The introduction of tuberculosis testing Xpert assay on GeneXpert platform by Cepheid is an example of such advancement. Such advances are anticipated to drive the global molecular diagnostics market.

Molecular Diagnostics Market Report Highlights

  • Reagents dominated the overall market majorly driven by the high usage rate of reagents due to the COVID-19 pandemic.
  • PCR technology accounted for a revenue share of 64.6% in 2021. The increased use of PCR for the diagnosis of COVID-19 and other infectious diseases is one of the major reasons for its dominance.
  • Self-testing or OTC segment is anticipated to be the fastest-growing segment, over the forecast period, as it facilitates early diagnosis and constant patient monitoring. The launch of COVID-19 molecular self-tests is also expected to boost the growth of this segment.
  • North America commanded the highest revenue share in 2021, driven by a high disease prevalence, proactive government measures, high testing rate for COVID-19, technological advancements, and improvements in healthcare infrastructure. .
Frequently Asked Questions about the Molecular Diagnostics Market

What is the estimated value of the Molecular Diagnostics Market?

The Molecular Diagnostics Market was estimated to be valued at $43.9 Billion in 2021.

What is the growth rate of the Molecular Diagnostics Market?

The growth rate of the Molecular Diagnostics Market is 1.7%, with an estimated value of $49.3 Billion by 2028.

What is the forecasted size of the Molecular Diagnostics Market?

The Molecular Diagnostics Market is estimated to be worth $49.3 Billion by 2028.

Who are the key companies in the Molecular Diagnostics Market?

Key companies in the Molecular Diagnostics Market include Abbott, Becton, Dickinson and Company, bioMérieux SA, Bio, Rad Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, Hologic, Inc. (Gen Probe) and Johnson & Johnson Services, Inc..
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • bioMérieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • GRIFOLs S.A.
  • Hologic, Inc. (Gen Probe)

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Secondary Sources
1.3.3 Primary Research
1.3.4 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Molecular Diagnostics Market Variables, Trends & Scope
3.1 Molecular Diagnostics Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 CLIA Waived Tests and Instruments
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increase in geriatric population
3.5.1.2 Introduction of technologically advanced products
3.5.1.3 Increase in demand for point-of-care facilities
3.5.1.4 Growing prevalence of target diseases
3.5.1.5 Increasing external funding for R&D
3.5.1.6 Outbreak of COVID-19
3.5.2 Market Restraint Analysis
3.5.2.1 Presence of ambiguous regulatory framework
3.5.2.2 High prices of molecular diagnostics tests
3.6 Molecular Diagnostics Market Analysis Tools
3.6.1 Porter’s Five Forces Analysis
3.6.2 SWOT Analysis; by factor (Political & Legal, Economic and Technological)
3.6.3 Major Deals & Strategic Alliances Analysis
3.6.3.1 New product launch
3.6.3.2 Mergers and acquisitions
3.6.3.3 Expansion
3.6.3.4 Partnerships
3.6.3.5 Marketing & promotions
3.6.3.6 Market entry strategies
Chapter 4 Molecular Diagnostics Market-Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.1.1 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
4.1.2 Innovators
4.1.3 Key Differentiators
4.2 Vendor Landscape
4.2.1 List of key distributors
4.2.2 Key Company Market Share Analysis, 2021
4.2.2.1 Global company market share analysis, by Application, 2021
4.2.2.1.1 Global company market share analysis, Molecular diagnostics, Oncology, 2021
4.2.2.1.2 Global company market share analysis, Molecular diagnostics, Pharmacogenomics, 2021
4.2.2.1.3 Global company market share analysis, Molecular diagnostics, Infectious Diseases, 2021
4.2.2.1.4 Global company market share analysis, Molecular diagnostics, Genetic Testing, 2021
4.2.2.1.5 Global company market share analysis, Molecular diagnostics, Others (Neurological disease, Cardiovascular Diseases, Microbiology, Others) 2021
4.2.2.2 Global company market share analysis, by Technology, 2021
4.2.2.2.1 Global company market share analysis, Molecular diagnostics, Polymerase Chain Reaction, 2021
4.2.2.2.2 Global company market share analysis, Molecular diagnostics, In Situ Hybridization, 2021
4.2.2.2.3 Global company market share analysis, Molecular diagnostics, INAAT, 2021
4.2.2.2.4 Global company market share analysis, Molecular diagnostics, Chips & Microarrays, 2021
4.2.2.2.5 Global company market share analysis, Molecular diagnostics, Mass Spectrometry, 2021
4.2.2.2.6 Global company market share analysis, Molecular diagnostics, Sequencing, 2021
4.2.2.2.7 Global company market share analysis, Molecular diagnostics, Transcription Mediated Amplification, 2021
4.3 Public Companies
4.3.1 Company Market Position Analysis (2021)
4.3.2 Competitive Dashboard Analysis
4.4 Private Companies
4.4.1 List of Key Emerging Companies /Technology Disruptors/Innovators
4.4.2 Regional Network Map
4.4.3 Competitive Dashboard Analysis
Chapter 5 Product Business Analysis
5.1 Molecular Diagnostics Market: Products Movement Analysis
5.1.1 Instruments
5.1.1.1 Instruments market estimates and forecast, 2017-2030 (USD Million)
5.1.2 Reagents
5.1.2.1 Reagents market estimates and forecast, 2017-2030 (USD Million)
5.1.3 Others
5.1.3.1 Others market estimates and forecast, 2017-2030 (USD Million)
Chapter 6 Test Location Business Analysis
6.1 Molecular Diagnostics Market: Test Location Movement Analysis
6.1.1 Point-of-Care
6.1.1.1 Point-of-care market estimates and forecast, 2017-2030 (USD Million)
6.1.2 Self-testing or Over the Counter
6.1.2.1 Self-testing or over the counter market estimates and forecast, 2017-2030 (USD Million)
6.1.3 Central Laboratories
6.1.3.1 Central laboratories market estimates and forecast, 2017-2030 (USD Million)
Chapter 7 Technology Business Analysis
7.1 Molecular Diagnostics Market: Technology Movement Analysis
7.1.1 Polymerase Chain Reaction (PCR)
7.1.1.1 Polymerase chain reaction market estimates and forecast, 2017-2030 (USD Million)
7.1.1.2 Nucleic acid extraction and purification
7.1.1.3 Nucleic Acid Extraction and purification market estimates and forecast, 2017-2030 (USD Million)
7.1.1.4 Others
7.1.1.5 Others market estimates and forecast, 2017-2030 (USD Million)
7.1.1.6 Polymerase chain reaction market, by Type
7.1.1.6.1 Multiplex PCR
7.1.1.6.1.1 Multiplex PCR market estimates and forecast, 2017-2030 (USD Million)
7.1.1.6.2 Other PCR
7.1.1.6.2.1 Other PCR market estimates and forecast, 2017-2030 (USD Million)
7.1.1.7 Polymerase chain reaction market, by Product
7.1.1.7.1 Instruments
7.1.1.7.1.1 Instruments PCR market estimates and forecast, 2017-2030 (USD Million)
7.1.1.7.2 Reagents
7.1.1.7.2.1 Reagents PCR market estimates and forecast, 2017-2030 (USD Million)
7.1.1.7.3 Others
7.1.1.7.3.1 Others PCR market estimates and forecast, 2017-2030 (USD Million)
7.1.2 In Situ Hybridization (ISH)
7.1.2.1 In Situ Hybridization market estimates and forecast, 2017-2030 (USD Million)
7.1.2.2 Instruments
7.1.2.2.1 Instruments ISH market estimates and forecast, 2017-2030 (USD Million)
7.1.2.3 Reagents
7.1.2.3.1 Reagents ISH market estimates and forecast, 2017-2030 (USD Million)
7.1.2.4 Others
7.1.2.4.1 Others ISH market estimates and forecast, 2017-2030 (USD Million)
7.1.3 INAAT
7.1.3.1 INAAT market estimates and forecast, 2017-2030 (USD Million)
7.1.3.2 Instruments
7.1.3.2.1 Instruments INAAT market estimates and forecast, 2017-2030 (USD Million)
7.1.3.3 Reagents
7.1.3.3.1 Reagents INAAT market estimates and forecast, 2017-2030 (USD Million)
7.1.3.4 Others
7.1.3.4.1 Others INAAT market estimates and forecast, 2017-2030 (USD Million)
7.1.4 Chips and Microarrays
7.1.4.1 Chips and Microarrays market estimates and forecast, 2017-2030 (USD Million)
7.1.4.2 Instruments
7.1.4.2.1 Instruments chips and microarrays market estimates and forecast, 2017-2030 (USD Million)
7.1.4.3 Reagents
7.1.4.3.1 Reagents chips and microarrays market estimates and forecast, 2017-2030 (USD Million)
7.1.4.4 Others
7.1.4.4.1 Others chips and microarrays market estimates and forecast, 2017-2030 (USD Million)
7.1.5 Mass Spectrometry
7.1.5.1 Mass Spectrometry market estimates and forecast, 2017-2030 (USD Million)
7.1.5.2 Instruments
7.1.5.2.1 Instruments mass spectrometry market estimates and forecast, 2017-2030 (USD Million)
7.1.5.3 Reagents
7.1.5.3.1 Reagents mass spectrometry market estimates and forecast, 2017-2030 (USD Million)
7.1.5.4 Others
7.1.5.4.1 Others mass spectrometry market estimates and forecast, 2017-2030 (USD Million)
7.1.6 Sequencing
7.1.6.1 Sequencing market estimates and forecast, 2017-2030 (USD Million)
7.1.6.2 Instruments
7.1.6.2.1 Instruments sequencing market estimates and forecast, 2017-2030 (USD Million)
7.1.6.3 Reagents
7.1.6.3.1 Reagents sequencing market estimates and forecast, 2017-2030 (USD Million)
7.1.6.4 Others
7.1.6.4.1 Others sequencing market estimates and forecast, 2017-2030 (USD Million)
7.1.7 Transcription Mediated Amplification (TMA)
7.1.7.1 Transcription mediated amplification market estimates and forecast, 2017-2030 (USD Million)
7.1.7.2 Instruments
7.1.7.2.1 Instruments TMA market estimates and forecast, 2017-2030 (USD Million)
7.1.7.3 Reagents
7.1.7.3.1 Reagents TMA market estimates and forecast, 2017-2030 (USD Million)
7.1.7.4 Others
7.1.7.4.1 Others TMA market estimates and forecast, 2017-2030 (USD Million)
7.1.8 Others
7.1.8.1 Others market estimates and forecast, 2017-2030 (USD Million)
7.1.8.2 Instruments
7.1.8.2.1 Instruments others market estimates and forecast, 2017-2030 (USD Million)
7.1.8.3 Reagents
7.1.8.3.1 Reagents others market estimates and forecast, 2017-2030 (USD Million)
7.1.8.4 Others
7.1.8.4.1 Others market estimates and forecast, 2017-2030 (USD Million)
Chapter 8 Application Business Analysis
8.1 Molecular Diagnostics Market: Application Movement Analysis
8.1.1 Oncology
8.1.1.1 Oncology market estimates and forecast, 2017-2030 (USD Million)
8.1.1.2 Breast cancer
8.1.1.2.1 Breast cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.3 Prostate cancer
8.1.1.3.1 Prostate cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.4 Colorectal cancer
8.1.1.4.1 Colorectal cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.5 Cervical cancer
8.1.1.5.1 Cervical cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.6 Kidney cancer
8.1.1.6.1 Kidney cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.7 Liver cancer
8.1.1.7.1 Liver cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.8 Blood cancer
8.1.1.8.1 Blood cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.9 Lung cancer
8.1.1.9.1 Lung cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.1.10 Other cancers
8.1.1.10.1 Other cancer market estimates and forecast, 2017-2030 (USD Million)
8.1.2 Pharmacogenomics
8.1.2.1 Pharmacogenomics market estimates and forecast, 2017-2030 (USD Million)
8.1.3 Infectious Diseases
8.1.3.1 Infectious Diseases market estimates and forecast, 2017-2030 (USD Million)
8.1.3.2 Methicillin-resistant Staphylococcus Aureus (MRSA)
8.1.3.2.1 MRSA market estimates and forecast, 2017-2030 (USD Million)
8.1.3.3 Clostridium difficile
8.1.3.3.1 Clostridium difficile market estimates and forecast, 2017-2030 (USD Million)
8.1.3.4 Vancomycin-Resistant Enterococci (VRE)
8.1.3.4.1 VRE market estimates and forecast, 2017-2030 (USD Million)
8.1.3.5 Carbapenem-resistant bacteria
8.1.3.5.1 Carbapenem-resistant bacteria market estimates and forecast, 2017-2030 (USD Million)
8.1.3.6 Flu
8.1.3.6.1 Flu market estimates and forecast, 2017-2030 (USD Million)
8.1.3.7 Respiratory Syncytial Virus (RSV)
8.1.3.7.1 RSV market estimates and forecast, 2017-2030 (USD Million)
8.1.3.8 Candida
8.1.3.8.1 Candida market estimates and forecast, 2017-2030 (USD Million)
8.1.3.9 Tuberculosis (TB) and drug-resistant TB
8.1.3.9.1 TB and drug-resistant TB market estimates and forecast, 2017-2030 (USD Million)
8.1.3.10 Meningitis
8.1.3.10.1 Meningitis market estimates and forecast, 2017-2030 (USD Million)
8.1.3.11 Gastrointestinal panel testing
8.1.3.11.1 Gastrointestinal panel testing market estimates and forecast, 2017-2030 (USD Million)
8.1.3.12 Chlamydia
8.1.3.12.1 Chlamydia market estimates and forecast, 2017-2030 (USD Million)
8.1.3.13 Gonorrhea
8.1.3.13.1 Gonorrhea market estimates and forecast, 2017-2030 (USD Million)
8.1.3.14 HIV
8.1.3.14.1 HIV market estimates and forecast, 2017-2030 (USD Million)
8.1.3.15 Hepatitis C
8.1.3.15.1 Hepatitis C market estimates and forecast, 2017-2030 (USD Million)
8.1.3.16 Hepatitis B
8.1.3.16.1 Hepatitis B market estimates and forecast, 2017-2030 (USD Million)
8.1.3.17 Other infectious disease market
8.1.3.17.1 Other infectious disease market estimates and forecast, 2017-2030 (USD Million)
8.1.4 Genetic Testing
8.1.4.1 Genetic testing market estimates and forecast, 2017-2030 (USD Million)
8.1.4.2 Newborn screening
8.1.4.2.1 Newborn screening market estimates and forecast, 2017-2030 (USD Million)
8.1.4.3 Predictive and presymptomatic testing
8.1.4.3.1 Predictive and presymptomatic testing market estimates and forecast, 2017-2030 (USD Million)
8.1.4.4 Other genetic testing
8.1.4.4.1 Other genetic testing market estimates and forecast, 2017-2030 (USD Million)
8.1.5 Neurological Diseases
8.1.5.1 Neurological diseases market estimates and forecast, 2017-2030 (USD Million)
8.1.6 Cardiovascular Diseases
8.1.6.1 Cardiovascular diseases market estimates and forecast, 2017-2030 (USD Million)
8.1.7 Microbiology
8.1.7.1 Microbiology market estimates and forecast, 2017-2030 (USD Million)
8.1.8 Others
8.1.8.1 Others market estimates and forecast, 2017-2030 (USD Million)
Chapter 9 Regional Business Analysis
9.1 Molecular Diagnostics Market: Regional Movement Analysis
9.1.1 North America
9.1.2 North America, SWOT Analysis
9.1.2.1 North America market estimates and forecast, 2017-2030 (USD Million)
9.1.2.2 U.S.
9.1.2.2.1 U.S. market estimates and forecast, 2017-2030 (USD Million)
9.1.2.3 Canada
9.1.2.3.1 Canada market estimates and forecast, 2017-2030 (USD Million)
9.1.3 Europe
9.1.4 Europe, SWOT Analysis
9.1.4.1 Europe market estimates and forecast, 2017-2030 (USD Million)
9.1.4.2 U.K.
9.1.4.2.1 U.K. market estimates and forecast, 2017-2030 (USD Million)
9.1.4.3 Germany
9.1.4.3.1 Germany market estimates and forecast, 2017-2030 (USD Million)
9.1.4.4 France
9.1.4.4.1 France market estimates and forecast, 2017-2030 (USD Million)
9.1.4.5 Spain
9.1.4.5.1 Spain market estimates and forecast, 2017-2030 (USD Million)
9.1.4.6 Italy
9.1.4.6.1 Italy market estimates and forecast, 2017-2030 (USD Million)
9.1.4.7 Belgium
9.1.4.7.1 Belgium market estimates and forecast, 2017-2030 (USD Million)
9.1.4.8 Switzerland
9.1.4.8.1 Switzerland market estimates and forecast, 2017-2030 (USD Million)
9.1.4.9 Netherlands
9.1.4.9.1 Netherlands market estimates and forecast, 2017-2030 (USD Million)
9.1.4.10 Poland
9.1.4.10.1 Poland market estimates and forecast, 2017-2030 (USD Million)
9.1.4.11 Austria
9.1.4.11.1 Austria market estimates and forecast, 2017-2030 (USD Million)
9.1.4.12 Greece
9.1.4.12.1 Greece market estimates and forecast, 2017-2030 (USD Million)
9.1.4.13 Sweden
9.1.4.13.1 Sweden market estimates and forecast, 2017-2030 (USD Million)
9.1.4.14 Turkey
9.1.4.14.1 Turkey market estimates and forecast, 2017-2030 (USD Million)
9.1.4.15 Finland
9.1.4.15.1 Finland market estimates and forecast, 2017-2030 (USD Million)
9.1.5 Asia Pacific
9.1.6 Asia Pacific, SWOT Analysis
9.1.6.1 Asia Pacific market estimates and forecast, 2017-2030 (USD Million)
9.1.6.2 Japan
9.1.6.2.1 Japan market estimates and forecast, 2017-2030 (USD Million)
9.1.6.3 China
9.1.6.3.1 China market estimates and forecast, 2017-2030 (USD Million)
9.1.6.4 India
9.1.6.4.1 India market estimates and forecast, 2017-2030 (USD Million)
9.1.6.5 Australia
9.1.6.5.1 Australia market estimates and forecast, 2017-2030 (USD Million)
9.1.6.6 New Zealand
9.1.6.6.1 New Zealand market estimates and forecast, 2017-2030 (USD Million)
9.1.6.7 Sri Lanka
9.1.6.7.1 Sri Lanka market estimates and forecast, 2017-2030 (USD Million)
9.1.6.8 Malaysia
9.1.6.8.1 Malaysia market estimates and forecast, 2017-2030 (USD Million)
9.1.6.9 Thailand
9.1.6.9.1 Thailand market estimates and forecast, 2017-2030 (USD Million)
9.1.6.10 Vietnam
9.1.6.10.1 Vietnam market estimates and forecast, 2017-2030 (USD Million)
9.1.6.11 Singapore
9.1.6.11.1 Singapore market estimates and forecast, 2017-2030 (USD Million)
9.1.7 Latin America
9.1.8 Latin America, SWOT Analysis
9.1.8.1 Latin America market estimates and forecast, 2017-2030 (USD Million)
9.1.8.2 Brazil
9.1.8.2.1 Brazil market estimates and forecast, 2017-2030 (USD Million)
9.1.8.3 Mexico
9.1.8.3.1 Mexico market estimates and forecast, 2017-2030 (USD Million)
9.1.8.4 Colombia
9.1.8.4.1 Colombia market estimates and forecast, 2017-2030 (USD Million)
9.1.8.5 Chile
9.1.8.5.1 Chile market estimates and forecast, 2017-2030 (USD Million)
9.1.8.6 Peru
9.1.8.6.1 Peru market estimates and forecast, 2017-2030 (USD Million)
9.1.8.7 Argentina
9.1.8.7.1 Argentina market estimates and forecast, 2017-2030 (USD Million)
9.1.9 Middle East & Africa
9.1.10 Middle East & Africa, SWOT Analysis
9.1.11 Middle East & Africa market estimates and forecast, 2017-2030 (USD Million)
9.1.11.1 South Africa
9.1.11.1.1 South Africa market estimates and forecast, 2017-2030 (USD Million)
9.1.11.2 Saudi Arabia
9.1.11.2.1 Saudi Arabia market estimates and forecast, 2017-2030 (USD Million)
9.1.11.3 Jordan
9.1.11.3.1 Jordan market estimates and forecast, 2017-2030 (USD Million)
9.1.11.4 United Arab Emirates
9.1.11.4.1 United Arab Emirates market estimates and forecast, 2017-2030 (USD Million)
9.1.11.5 Qatar
9.1.11.5.1 Qatar market estimates and forecast, 2017-2030 (USD Million)
9.1.11.6 Nigeria
9.1.11.6.1 Nigeria market estimates and forecast, 2017-2030 (USD Million)
9.1.11.7 Egypt
9.1.11.7.1 Egypt market estimates and forecast, 2017-2030 (USD Million)
Chapter 10 Company Profile
10.1 Market Participation Categorization
10.2 Company Profiles
10.2.1 Abbott
10.2.1.1 Company overview
10.2.1.2 Alere, Inc.
10.2.1.3 Financial performance
10.2.1.4 Product benchmarking
10.2.1.5 Strategic initiatives
10.2.2 Becton, Dickinson and Company
10.2.2.1 Company overview
10.2.2.2 Financial performance
10.2.2.3 Product benchmarking
10.2.2.4 Strategic initiatives
10.2.3 bioMérieux SA
10.2.3.1 Company overview
10.2.3.2 Financial performance
10.2.3.3 Product benchmarking
10.2.3.4 Strategic initiatives
10.2.4 Bio-Rad Laboratories, Inc.
10.2.4.1 Company overview
10.2.4.2 Financial performance
10.2.4.3 Product benchmarking
10.2.4.4 Strategic initiatives
10.2.5 Agilent Technologies, Inc.
10.2.5.1 Company overview
10.2.5.2 Financial performance
10.2.5.3 Product benchmarking
10.2.5.4 Strategic initiatives
10.2.6 Danaher Corporation
10.2.6.1 Company overview
10.2.6.2 Cepheid
10.2.6.3 Beckman Coulter
10.2.6.4 Leica Biosystems
10.2.6.5 Financial performance
10.2.6.6 Product benchmarking
10.2.6.7 Strategic initiatives
10.2.6.8 Strategic initiatives of Cepheid
10.2.6.9 Strategic initiatives of Beckman Coulter, Inc.
10.2.6.10 Strategic initiatives of Leica Biosystems
10.2.7 Hologic, Inc. (Gen Probe)
10.2.7.1 Company overview
10.2.7.2 Financial performance
10.2.7.3 Product benchmarking
10.2.7.4 Strategic initiatives
10.2.8 Illumina, Inc.
10.2.8.1 Company overview
10.2.8.2 Financial performance
10.2.8.3 Product benchmarking
10.2.8.4 Strategic initiatives
10.2.9 Johnson & Johnson Services, Inc.
10.2.9.1 Company overview
10.2.9.2 Financial performance
10.2.9.3 Product benchmarking
10.2.9.4 Strategic initiatives
10.2.10 GRIFOLs S.A.
10.2.10.1 Company overview
10.2.10.2 Financial performance
10.2.10.3 Product benchmarking
10.2.10.4 Strategic initiatives
10.2.11 Qiagen
10.2.11.1 Company overview
10.2.11.2 Financial performance
10.2.11.3 Product benchmarking
10.2.11.4 Strategic initiatives
10.2.12 F. Hoffmann-La Roche Ltd
10.2.12.1 Company overview
10.2.12.2 Financial performance
10.2.12.3 Product benchmarking
10.2.12.4 Strategic initiatives
10.2.13 Siemens Healtineers
10.2.13.1 Company overview
10.2.13.2 Financial performance
10.2.13.3 Product benchmarking
10.2.13.4 Strategic initiatives
10.2.14 Sysmex Corporation
10.2.14.1 Company overview
10.2.14.2 Financial performance
10.2.14.3 Product benchmarking
10.2.14.4 Strategic initiatives
Note: Product cover images may vary from those shown
  • Abbott
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Hologic, Inc. (Gen Probe)
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • GRIFOLs S.A.
  • Qiagen
  • F. Hoffmann-La Roche Ltd
  • Siemens Healtineers
  • Sysmex Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...